IMPORTANCE Written exposure therapy (WET), a 5-session intervention, has been shown to efficaciously treat posttraumatic stress disorder (PTSD). However, this treatment has not yet been directly compared with a first-line PTSD treatment such as cognitive processing therapy (CPT).
T he recently revised Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder (PTSD) and Acute Stress Disorder 1 strongly recommends the use of individual, manualized trauma-focused psychotherapies that have a primary component of exposure and/or cognitive restructuring, such as prolonged exposure 2 and cognitive processing therapy (CPT). 3 Also included in this recommended group of treatments is written narrative exposure, which the clinical practice guideline notes is a simple, yet effective, way to deliver exposure therapy for PTSD.
1
Included among written narrative exposure treatments is written exposure therapy (WET), a brief (ie, 5 sessions) traumafocused intervention in which individuals are asked to write about their traumatic experience following scripted instruction. The first session includes psychoeducation about PTSD along with a treatment rationale followed by 30 minutes of writing. At the beginning of each subsequent session, therapists provide feedback to individuals about the degree to which they followed the writing instructions during the prior session and offer suggestions for adhering to the treatment protocol. After this feedback, individuals write for 30 minutes without interruption. Written exposure therapy does not include any assignments between sessions. Written exposure therapy also involves considerably less therapist training and supervision to successfully implement than do either prolonged exposure or CPT. Prior research has shown WET to significantly reduce the severity of PTSD symptoms in a variety of trauma survivors, with effect sizes similar to those associated with CPT and prolonged exposure, 4 and to have substantially fewer treatment dropouts than these other treatments. 4 ,5 However, WET
has not yet been directly compared with either of these treatments in the same study. This study examined if WET is noninferior to CPT. Cognitive processing therapy was selected because it is widely recognized as a first-line treatment approach for PTSD and is 1 of 2 treatments that has the strongest empirical support. Also, CPT includes a written narrative account as part of the treatment and the developer of CPT (one of us, P.A.R.) agreed to oversee supervision and training of the CPT arm of the study, thereby ensuring high-quality administration of this treatment. We expected that individuals who were randomly assigned to WET would report reductions in PTSD symptoms similar to those seen in individuals assigned to CPT. Consistent with findings on treatment dropout from prior studies, 4, 6 we also expected significantly less treatment dropout for WET relative to CPT.
Methods

Participants
Demographic characteristics are displayed in Table 1 . Participants were 126 adults (60 women and 66 men) aged 18 years or older seeking treatment for PTSD in Boston, Massachusetts. Recruitment was designed to be broadly inclusive. Eligibility required meeting DMS-5 7 criteria for PTSD and, if taking psychotropic medication, taking a stable dose for at least 4 weeks. Participants were asked to keep their medication regimen unchanged throughout the treatment period in consultation with their prescribers. Minimal exclusion criteria consisted of current high risk for suicide, active psychosis or mania, severe cognitive impairment, current diagnosis of substance dependence, and concurrent psychosocial treatment for PTSD. Figure 1 shows the CONSORT diagram for the specifics of recruitment and participation; eAppendix 1 in Supplement 1 provides a complete list of reasons for treatment noncompletion. The study was approved by the Boston University institutional review board and the Veterans Affairs Boston Healthcare System institutional review board. All participants provided written informed consent. The full study protocol can be found in Supplement 2.
Measures
Clinical interviews were administered by 4 independent evaluators who had at least a master's degree in psychology and who were blinded to treatment conditions. Assessments were conducted at baseline and 6, 12, 24, and 36 weeks after the first treatment session. Given the substantial difference in treatment sessions between the 2 treatments, a structured time approach for assessments was used rather than assessing after treatment and conducting follow-up from the completion of treatment. Assessment points were selected based on the approximate completion of WET (6 weeks) and CPT (12 weeks). The primary measure used to assess PTSD diagnostic status and symptom severity was the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). 8, 9 The Structured Clinical Interview for DSM-IV (SCID) 10 was used to assess for exclusion criteria and baseline psychiatric comorbidity. This measure was included at the baseline assessment only; the version of the SCID that corresponds to the DSM-5 was not available at the start of this study. Interrater reliability was very good (CAPS-5, κ = 0.85; SCID, κ = 0.78). To examine treatment dropout, we compared the number of participants in each treatment condition who left treatment before completion. We also assessed participants' beliefs about expected outcome of treatment at the end of the first treatment session using the Treatment Expectancy Questionnaire 11 and treatment satisfaction, assessed at the last treatment session, using the Client Satisfaction Measure.
Procedures
Participants were recruited from advertisements and direct referrals from community health care professionals. From February 28, 2013, to November 6, 2016, the research team prescreened 361 individuals for eligibility via telephone. Approximately 113 individuals were ineligible or declined participation. A total of 190 individuals consented to this study and completed an eligibility and baseline assessment and 126 were randomized. All study procedures took place at the Veterans Affairs Boston Healthcare System. Training and fidelity of independent evaluators are described in eAppendix 2 in Supplement 1.
Randomization and Blinding
After participants were deemed to be eligible, a study staff member who was not involved in the evaluations randomized participants using a computerized block randomization with a 1:1 allocation ratio to WET and CPT conditions. The project coordinator who was responsible for final determination of study eligibility was blinded to the randomization sequence. Participants were unaware of study hypotheses and were instructed not to reveal their randomization status to the independent evaluators prior to each assessment. To further protect blinding, independent evaluators were located separately from the therapists, and a new rater was assigned in the event of an unintentional unblinding.
Treatment
As previously described, WET includes 5 sessions in which patients are instructed to write about a specific traumatic event, with a focus on details of the event and thoughts and feelings that occurred during the event, for 30 minutes each session.
No assignments between sessions are included in WET. Cognitive processing therapy is a 12-session trauma-focused therapy in which patients are taught to recognize and challenge dysfunctional cognitions about their traumatic event and current thoughts about themselves, others, and the world. In the original CPT protocol (CPT plus written account), which was used in this study because it has been disseminated widely and has accumulated the most empirical support, individuals also write 2 trauma accounts. These accounts are written at home after sessions 3 and 4. In these written accounts, participants provide sensory details, thoughts, and feelings associated with the trauma. Unlimited time is allotted for the narrative and once it is completed patients are to read the account daily until the next session. In addition to these assignments to write 2 trauma accounts, additional between-session assignments are given after each treatment session. Cognitive Child nonsexual assault 11 (8.7) 6 (9.5) 5 (7.9)
Child sexual assault 20 (15.9) 9 (14.3) 11 (17.5)
Motor vehicle crash 10 (7.9) 5 (7.9) 5 (7.9)
Injury from other accidental causes 13 (10.3) 6 (9.5) 7 (11.1)
Abbreviations: CPT, cognitive processing therapy; WET, written exposure therapy.
a Percentages have been rounded and may not total 100.
processing therapy and WET were delivered individually and treatments consisted of weekly sessions. Consistent with the intent-to-treat approach, all individuals who dropped out of treatment prematurely were asked to complete all assessments included in the study. A structured protocol was used for each therapy condition. Training and fidelity of the therapists are described in detail in eAppendix 3 in Supplement 1. Adherence and competency ratings were good to excellent for both treatment conditions. For detailed information on study design, see the study by Sloan et al. 13 
Statistical Analysis
Because the noninferiority margin for CAPS-5 scores has not yet been determined, we calculated the reliable change index 14 to use as the noninferiority margin. Using the pooled SD (9.5) for CAPS-5 scores at baseline, and the published test-retest value for the CAPS-5 (r =0. 78), 9 the SE of the difference between the 2 groups was 6.28. With this information, we determined that the CAPS-5 reliable change index is 13 points. Thus, any difference between WET and CPT in CAPS-5 reliable change index scores greater than 13 points indicates that the difference is statistically significant and not owing to measurement error. Recognizing that a 13-point noninferiority margin may be too lenient, a more conservative 10-point noninferiority margin for the prior version of the CAPS was used. Sample size was determined using the module for noninferiority tests in the Power Analysis and Sample Size (PASS) Software.
15 Specifications were the 10-point noninferiority margin, an SD of 20 for CAPS-5 severity scores, 16 a true difference between treatment groups of 0, a 1-sided noninferiority test at P = .05, desired power of 0.80, and equal participant allocation to the 2 treatment groups. With these specifications, PASS indicated that 50 participants per group were required. This number was increased twice, first by 15% to account for unavoidable loss to follow-up, and then by an additional 10% to deal with the then-unknown psychometric properties of the CAPS-5; this increase resulted in a total sample size of 126. The sample size is similar 17 or larger than other PTSD noninferiority trials.
18,19
Hierarchical linear modeling 20 was also conducted to determine within-condition effect of treatment on symptoms of PTSD. All analyses were conducted using an unstructured covariance matrix. Analyses were conducted using all data points for all participants who were randomized (ie, intent to treat). Within-and between-condition effect sizes (Cohen d) were calculated and interpreted using guidelines from Cohen.
21
Results
Participants assigned to WET and CPT conditions did not significantly differ in age, educational level, or household income, and were not more likely in either condition to identify as male, Hispanic, or be a military veteran. Likewise, participants did not significantly differ in PTSD symptom severity at baseline (t 124 =-0.57;P =.57).
Treatment Process Measures
Participants assigned to CPT and WET did not significantly differ in terms of treatment expectations (t 123 = -1.57; P = .12), with generally high expectations indicated for both treatments 
PTSD Severity and Diagnosis
Descriptive statistics for outcome of PTSD symptoms are provided in Table 2 . This table also displays the CAPS-5 symptom severity treatment condition difference score. Withincondition hierarchical linear modeling analyses indicated that CAPS-5 total scores showed significant effects of linear change over time in both the WET (B = -2.33; SE = 0.35; t = -6.68; P < .001) and CPT (B = -3.43; SE = 0.44; t = -7.70; P < .001) conditions. In addition, a quadratic growth term explained significant variance over and above a linear term in both the WET (B = 0.80; SE = 0.23; t = 3.50; P = .001) and CPT (B = 1.05; SE = 0.25; t = 4.24; P < .001) conditions. Figure 2 illustrates mean difference between treatment conditions with 95% CIs for changes in CAPS-5 scores over time. The noninferiority hypothesis was supported by the finding that CAPS-5 severity scores for participants in the WET condition were noninferior to those for participants in the CPT condition at any assessment period. Within-condition effect sizes were large in both conditions for the 12-week through the 36-week assessments (Table 3) . With the exception of the 24-week assessment, between-condition effect sizes were small at the assessments (ie, <0.20). 21 The 24-week assessment between-condition effect size was 0.29, with CPT showing a slightly larger change from baseline than WET (4.31 points' difference between the 2 groups). Fewer than half of participants continued to meet diagnostic criteria for PTSD in both conditions at the 24-and 36-week follow-ups (Table 2) . Participants were not more likely to meet PTSD diagnostic criteria in one condition or the other at any assessment. We were unable to conduct a completer analysis owing to the significant difference between WET and CPT in the number of participants who dropped out of treatment. However, the difference between the 2 treatments is similar to that of the intent-to-treat sample (eTable in Supplement 1).
Adverse Events
Six patients randomized to CPT (9.5%) reported a total of 7 adverse events and 5 patients randomized to WET (7.9%) reported a total of 7 adverse events. There were no significant differences in the nature, frequency, or severity of adverse events reported. More details about events, which were primarily injuries or illnesses, are provided in eAppendix 4 in Supplement 1.
Discussion
Although prior studies have shown WET to significantly reduce PTSD symptoms among trauma survivors, no prior study had compared WET directly with another PTSD treatment strongly recommended in the revised Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder. 1 Our analyses indicate that WET did not differ from CPT in reducing symptoms of PTSD or in the percentage of participants who met diagnostic criteria for PTSD at any assessment point. Furthermore, participants assigned to the 2 treatments did not differ significantly in treatment expectations or the degree to which they were satisfied with the treatment they received.
Our results add to mounting research showing that the dose of therapy needed for beneficial outcomes for individuals with PTSD is not as large as what was once previously thought. 19, 22, 23 Our findings extend those prior studies by demonstrating that not only can PTSD symptoms be reduced significantly with less therapeutic exposure but that not as many therapy sessions 
10-Point noninferiority margin
The vertical axis represents differences between conditions in CAPS-5 total score changes; negative values indicate greater improvement in the written exposure therapy (WET) condition. CPT indicates cognitive processing therapy; PTSD, posttraumatic stress disorder; and RCI, reliable change index.
are required. The fact that fewer sessions and less exposure are necessary to result in beneficial outcomes underscores the need to investigate the necessary and sufficient treatment elements for successful outcomes. Written exposure therapy differs from CPT in other potentially important aspects. For instance, written narratives are conducted within the sessions for WET, whereas the narrative written trauma accounts are completed between sessions in CPT. Moreover, CPT has between-session assignments after each treatment session, whereas no between-session assignments are included in WET. The version of CPT used in this study included the written accounts that have been found to be associated with 15% more dropouts and with no value added in 1 study. 28 In our study, the dropouts typically occurred early in the course of treatment when the written trauma accounts were assigned. The dropout rate for CPT in our study is similar to that observed in other studies, 6 which have also noted a pattern of early treatment dropout. 29, 30 These findings suggest that it may be easier for individuals to complete written trauma accounts during treatment sessions within a clinic setting rather than as assignments to be completed outside of the clinic. Future research should examine whether dropout rates are reduced with the version of CPT that does not include written accounts. Overall, the greater treatment dropout rate in CPT in our study was not merely owing to more treatment sessions. It is also not the case that individuals dropped out of CPT prematurely because of perceived treatment gain; only 1 person stated this as the reason for premature treatment dropout. Although there were no significant differences between WET and CPT at any time point, we did find a somewhat larger between-group difference at the 24-week assessment. More important, this is the assessment time point that captures treatment completion for all CPT participants, although there was considerable variability within the CPT group for time to treatment completion. This slightly larger between-condition difference was not maintained at the next assessment at 36 weeks. Thus, it was not a difference that was maintained or grew over time.
Limitations
This study has some limitations that should be considered. First, a mixed trauma sample was examined rather than focus on a specific trauma sample, such as military veterans or individuals who experienced interpersonal violence. A mixed trauma sample was included to increase generalizability of the findings obtained. However, there is some evidence that trauma-focused PTSD treatments have lower efficacy with certain trauma samples, such as military veterans and military service members.
31 Accordingly, it would be important to investigate whether WET is noninferior to CPT using a sample of military veterans or military service members. Second, we were unable to conduct completer analyses owing to the significantly greater number of participants who dropped out of CPT. It could be argued that WET is better tolerated than CPT but could have a weaker effect size than CPT if only the individuals completing the full course of WET and CPT could be compared. Even with the 39.7% who dropped out early included, the outcomes for CPT were not significantly different than for WET. Nonetheless, the pattern of findings for the completer sample is similar to that of the intent-to-treat sample. Third, the noninferiority margin used in this study may need to be reexamined once additional data for CAPS-5 are available. Finally, we examined stability of psychotropic medication via self-report.
Conclusions
To our knowledge, this study is the first to directly compare WET, a brief exposure-based treatment approach, with CPT, a first-line PTSD treatment. Findings indicate that WET is noninferior to CPT despite the significantly reduced treatment dose with WET. The findings provide additional efficacy support for an efficient PTSD treatment that is well tolerated by patients. Written exposure therapy should be considered by clinicians to be a viable treatment option that can address some of the barriers to receiving and implementing CPT and prolonged exposure that have been noted in health care settings. a Overall study dropout, defined as withdrawing or declining to complete all study assessments, was 9.52% (n = 12; CPT, n = 9; WET, n = 3).
the integrity of the data and the accuracy of the Independent evaluators (IEs) with master's or doctoral degrees in psychology were trained to criterion to administer the CAPS-5 and SCID. IEs were masked to treatment condition. Each clinical assessment was audiotaped, and 20% of each IE's interviews were randomly selected (CAPS-5 n = 743; SCID n = 191) .Inter-rater reliability was very good (CAPS-5 = .85; SCID = .78). eAppendix 3. Therapists A total of 10 doctoral-level therapists completed a 2-day CPT workshop and 2 hour WET workshop prior to treating participants in the study. The same therapists were used for both arms of the study. All therapists received weekly supervision from the first or third author, who listened to recorded therapy sessions. One independent CPT and one independent WET clinician rated 20 % of randomly selected recorded treatment sessions using adherence and competence rating forms selected from prior studies.
4,28
Raters completed assessments of "unique and essential elements" for each rated session. Raters assessed adherence and competence according to a 7-point scale (1 = poor, 7 = excellent, with satisfactory as the midpoint). Average adherence by WET therapists was 5.81 (SD = 0.73), and average adherence by CPT therapists was 5.71 (SD = 0.60). Across all rated sessions, there were no instances in either condition in which raters identified the delivery of proscribed treatment elements. The average therapist competence score for WET was 6.15 (SD = 0.71), and the average CPT therapist competence score was 5.91 (SD = 0.89). Across all rated sessions in both conditions, 92.1% of adherence ratings were "good" to "excellent," and none were below "satisfactory." eAppendix 4. Adverse Events Eleven participants reported a total of 14 AEs. The majority of the AEs (57%) were medical in nature (e.g., surgery, pain, and falls). All of the psychiatric AEs were secondary to issues which predated the individuals' study involvement (e.g., alcohol and mania) or were otherwise unrelated to the study treatment (e.g., stress related to caring for a terminally ill family member). 12 of 37 (32.43%) Abbreviations: CAPS-5, Clinician Administered PTSD Scale for DSM-5; CPT, cognitive processing therapy; PTSD, post-traumatic stress disorder; WET, written exposure therapy.
IRB-approved Protocol
Posttraumatic stress disorder (PTSD) is a highly prevalent and chronic disorder. As a result of 4 the high prevalence rates and associated substantial impairment, PTSD represents a significant 5 public health problem. Although several evidence based-treatments (EBTs) for PTSD exist, 6
there are some good reasons to develop additional EBTs for PTSD. For example, a significant 7 minority of PTSD patients do not respond favorably to the available EBTs. Moreover, 8 approximately one-quarter of individuals in EBTs for PTSD prematurely ends treatment (i.e., 9
Hembree et al., 2003). Another issue concerns the lack of accessibility of EBTs for PTSD. This 10 lack of accessibility is likely the result of geographic, economic, and time commitment barriers. 11
Taken together, there is a strong need to develop alternative treatments for PTSD, especially 12 treatments that are efficient. Establishment of efficient PTSD treatments would constitute a 13 major milestone and would have substantial public health impact. 14 15
Written Exposure Therapy (WET) represents such an alternative PTSD treatment option. The 16 investigative team has conducted prior work establishing the efficacy of WET for PTSD. This 17 work also showed that WET is associated with remarkably low rates of treatment dropout (e.g., 18 8%). The proposed project represents the next step in this line of work by investigating whether 19
WET is non inferior to Cognitive Processing Therapy (CPT), an evidence-based PTSD 20 treatment. One hundred twenty-six (N = 126) men and women with a diagnosis of PTSD will be 21 randomly assigned to either WET or CPT. We expect to conduct initial assessments on up to 22 220 individuals in order to enroll 126 individuals into the clinical trial. Outcome data will be 23 collected at baseline and 6-, 12-, 24-, 36-, and 60-weeks post-baseline.
25
The primary specific aim is to examine whether WET results in a noninferior PTSD symptom 26 severity outcome relative to CPT.
27
Hypothesis 1: Participants randomly assigned to WET will show noninferior outcome in PTSD 28 symptom severity at the 12, 24, and 36-week post-baseline assessment, relative to participants 29 randomly assigned to CPT. 30 31
Hypothesis 2: Participants randomly assigned to WET will show noninferior outcome in PTSD 32 symptom severity at the 60 week post-baseline assessment, relative to participants randomly 33 assigned to CPT.
34
The secondary aim is to examine differences between the two treatment conditions in dropout 35 rate. 36 37 Hypothesis 3: WET will demonstrate a significantly lower dropout rate than CPT. 38 39
Exploratory analyses: We will also conduct several exploratory analyses to identify potential 40 moderators and mediators of treatment outcome. These analyses will be exploratory because 41 the empirical literature on moderators and mediators of PTSD treatment outcome is limited and 42 does not provide guidance for specific predictions. The proposed project is innovative in its goal to establish a treatment for PTSD that is efficient 53 and well-tolerated. Although there are EBTs for PTSD, these treatments are associated with 54 relatively high dropout rates and evidence indicates that a substantial subset of patients fail to 55 respond to these treatments (Kearns & Rothbaum, 2012) . Consequently, there is a great need 56 to develop alternative treatments for PTSD. We have developed an alternative treatment for 57 PTSD through a series of systematic studies and we have demonstrated that this treatment is 58 efficacious. We will now examine whether WET is noninferior to CPT. 59 60
Background 61
Research has shown that PTSD is a common occurrence among those who are 62 exposed to trauma. One of the most definitive epidemiological studies, the National Comorbidity for PTSD. In contrast to our earlier findings, results revealed no significant PTSD symptom 134 severity reduction for individuals randomly assigned to the written disclosure condition, relative 135 to individuals assigned to a control writing condition. Importantly, the results also showed that 136 participants assigned to the written disclosure condition did not experience a significant 137 reduction in arousal and negative affect from the first to the last session. This finding suggested 138 that the therapeutic dose (three, 20 minute writing sessions) was not sufficient to produce 139 beneficial outcome. However, the lack of group differences might have occurred for other 140 reasons, such as study participants were not treatment seeking. Because all of the work that has been conducted with WET has focused on the civilian 188 population, we conducted an unpublished, uncontrolled pilot study to examine the feasibility and 189 tolerability of WET with veterans diagnosed with PTSD (2 were 100% service connected for 190 PTSD). Of the 7 veterans that enrolled in the trial, one dropped out of treatment (14% treatment 191 dropout) but this veteran returned for all subsequent assessment sessions. PTSD symptom 192 severity was assessed using a semi-structured diagnostic interview (i.e., CAPS) administered at believe it is premature to solely focus on a veteran population for this RCT. Thus, any adult with 198 a diagnosis of PTSD will be included in the proposed RCT. We expect that some participants in 199 the RCT will be veterans (combat-related PTSD) and we plan to examine whether type of 200 trauma event moderates outcome for both treatments included in this study. In addition to examining the efficacy of WET, we also have investigated participants' 215 emotional responding during the WET sessions. We found evidence of both initial activation (via 216 self-report, heart rate, and salivary cortisol) among participants assigned to the WET condition 217 during the first session, relative to participants assigned to the control writing condition. We also 218 observed a significant reduction in activation from the first session to the last session for the 219 WET condition only (i.e., habituation) (Sloan & Marx, 2004; . 220 221
These findings were promising, however, we recognized that our prior studies could be 222 improved upon. For example, in our initial studies, we did not require participants to meet 223 criteria for PTSD and all the treatment outcomes were assessed using self-report measures.
224
We also recognized that the WET protocol did not include any information psychoeducation or 225 treatment rationale. We rectified this by adding these components to subsequent iterations of 226 the WET protocol. Lastly, we found that 3 WET sessions did not promote sufficient habituation 227 of pathological fear responding and, consequently, did not result in significant reductions in 228 PTSD symptom severity for individuals meeting diagnostic criteria for PTSD Efficacy of WET as an intervention for PTSD. After completing treatment development work 241 on the WET protocol, we conducted an efficacy of study of WET as an intervention for MVA-242 related PTSD (R34MH077658-02). In this RCT, participants were randomized to either WET (n 243 = 24) or wait-list (WL; n = 24). We enrolled 79% of those assessed over a 15 month period 244 (average of 3 participants per month). Median time since MVA was 20 months, and all of the 245 participants were diagnosed with chronic PTSD. Participants were recruited from the greater 246
Boston area and were racially diverse (38% Caucasian, 35% African-American, 8% Hispanic, 247 6% Asian-American, 13% "other"). The average age was 40.5 years (SD = 12.9), 65% were 248 women and 75% of the participants reported an annual household income of $35,000 or less. 249 Given the favorable findings for WET, the next step in examining the efficacy of this 316 treatment is to compare it directly with an established EBT for PTSD. In this study, we will 317 conduct a noninferiority RCT in which we compare WET with CPT. 318 319
320
Efficacy of WET with veterans. Because all of the work that has been conducted with WET 321 has focused on the civilian population, we recently 322 conducted an uncontrolled pilot study to examine the 323 feasibility and tolerability of WET with veterans 324 diagnosed with PTSD (2 were 100% service 325 connected for PTSD). Of the 7 veterans that 326 enrolled in the trial, one dropped out of treatment 327 (14% treatment dropout); this veteran returned for all 328 subsequent assessment sessions. PTSD symptom 329 severity was assessed using a semi-structured 330 diagnostic interview (i.e., CAPS) administered at pre-331 and post-treatment, and a 3 month follow-up. 332 Findings indicated large within group effect size at both post-treatment (d = 1.0) and 3 month 333 follow-up (d =1.4). In addition, five of the seven veterans no longer met PTSD diagnostic 334 criteria following WET. Veterans reported high treatment satisfaction as well. Although the 335 findings from the pilot trial are encouraging, we believe it is premature to solely focus on a 336 veteran population for this RCT. Thus, participants in the proposed study will be adults with a 337 diagnosis of PTSD. We expect that some participants who enroll in the RCT will be veterans 338 (combat-related PTSD). We plan to examine whether type of trauma event moderates outcome 339 for both treatments included in this study. experience recruiting PTSD participants from the community. Although we used a variety of 345 recruitment strategies in our recently completed RCT, two strategies were most effective. These 346 strategies were 1) posting flyer announcements in the community (e.g., near public 347 transportation stops, in community centers, public libraries, laundromats, grocery stores) and 2) 348 posting announcements on Craigslist. Through these methods, we were able to recruit 3 349 participants per month, on average, who met eligibility criteria and enrolled in the RCT. We 350 expect to recruit a greater number of participants for the proposed RCT because we will be 351 recruiting a more diverse sample of PTSD participants in terms of the index trauma. In addition, 352
we will recruit from community centers in the greater Boston area (e.g., Boston Rape 353
Counseling Center) and we will use the Boston University RESPECT registry as an additional 354 recruitment strategies.
356
Diagnostic Procedures, including Training and determination of reliability: The CAPS and 357 the Structured Clinical Interview for DSM--IV (SCID) will be used to establish current PTSD 358 diagnosis, to characterize current co-morbid psychiatric problems, and to rule out current 359 psychosis, bipolar disorder and substance dependence. Clinical staff with at least a master's 360 degree will be trained in the administration of these instruments, following the procedures 361 outlined by DiNardo et al. (1993) . These procedures include successfully matching criterion 362 diagnoses for 3 of 5 training tapes, as well as demonstrating competency in administering 363 interviews. Training in diagnostic procedures will occur in a 1-day workshop with all assessors, 364
to be conducted at the start of the project. The training workshop will be videotaped, allowing for 365 consistency when adding new assessors. Additionally, all assessment staff will rate 366 standardized diagnostic interviews (once every 3 months) to prevent rater drift. This technology 367 will also permit standardized training of assessors who join the project after the initial training 368
workshop. Assessors will be certified to administer the CAPS and SCID when they match 369 criterion diagnoses and competently administer these instruments during a supervised 370 interview. Throughout the trial, all interviews will be recorded and 10% will be selected at 371 random for review by an Independent Reliability Evaluator. This individual will watch the taped 372 interview and provide a diagnostic profile. S/he will remain unaware as to participants' treatment 373 condition assignment or the assessment time-point, in order to permit objective assessment of 374 diagnostic reliability. Discrepancies between the Independent Reliability Evaluator's and the 375 independent assessor's ratings will be resolved through consultation with the PI. 376
In addition to these training procedures, the assessors will present all diagnostic 377 assessments conducted within the past week at a weekly assessment staff meeting lead by Dr. 378
Marx. 379 380
Independent Assessors: The independent assessors will be unaware of treatment condition 381 assignment of participants. Assessor will be housed in office space that will be located on a 382 different floor than the floor where treatment sessions will be conducted and where study 383 therapists will be housed (the National Center for PTSD has space on several floors of the 14 384 story VA Boston Healthcare System). Separating the location of the therapists and the 385 independent assessors will help to ensure that assessors remain blinded to treatment condition.
386
In addition, participants will be instructed to not disclose to the assessors which treatment 387 condition they have been assigned to and the identity of their therapist. Lastly, the blinding 388 procedures will be checked by asking the independent assessors at each assessment occasion 389 to complete a questionnaire regarding whether any information was revealed that might indicate 390 the treatment condition assignment of the participant. Independent assessors will be trained 391 and supervised by Dr. Marx.
392
CAPS-5 The CAPS-5 is a semi-structured interview for evaluating PTSD and is the version that 393 corresponds to PTSD diagnostic criteria that will be in DSM-5; this has been officially approved 394 by American Psychiatric Association. The CAPS will be scored in two ways; presence or 395 absence of DSM-5 PTSD and an overall symptom severity score, computed by summing the 396 total of each symptom score (frequency + intensity). 397 398
The Trauma Life Experience Questionnaire (TLEQ; Kubany et al., 2000) will be completed at 399 baseline to assess lifetime history of exposure to traumatic life events and responses to these 400 experiences. The TLEQ has strong psychometric properties and is commonly used to assess 401 trauma history. We will use the TLEQ to identify the frequency and type of trauma events 402 experienced by participants for the purpose of exploring the extent to which trauma history may 403 serve as a moderator of treatment outcome. This measure will also be used to identify the 404 trauma index event for which the CAPS should be administered. PTSD Checklist -5 (PCL5) is a 17-item self-report measure of PTSD that corresponds to the 435 DSM-V symptoms of PTSD. Like the CAPS, the PCL5 can be scored to yield an overall severity 436 score (total score). The PCL will be included in the proposed study to monitor PTSD symptom 437 severity during the treatment phase (see Protection of Human Subjects section), and will also 438 be completed at each assessment occasion. 439 440
The Beck Depression Inventory-II (BDI-II; Beck et al., 1996) will be administered to assess 441 depression symptom severity. This 21-item self-report questionnaire evaluates current 442 depressive symptoms and has well-established reliability and validity (Dozois et al., 1998) . The 443 BDI-II will be included in the proposed study to examine changes in depression symptom 444 severity associated with treatment, as well as to assess any changes in suicidal ideation. The 445 BDI-II will be completed at each assessment occasion and at each treatment session.
447
The Client Satisfaction Questionnaire (Larsen, et al., 1979 This measure will be completed at each treatment session and will be used to examine 463 emotion regulation strategies as a mediator of treatment outcome. The measure will also 464 be completed at each assessment occasion. We chose this measure because of its 465 ability to index general cognition rather than content specific cognitions (e.g., 466
Posttraumatic Cognition Inventory). In addition, the CERQ-S is currently being used by 467
Dr. Resick The therapeutic alliance will be assessed using the 12-item therapist and client versions of the 512
Working Alliance Inventory (WAI; Horvath & Greenberg, 1989; Tracey & Kokotovic, 1989) . In 513 addition to the total score, the WAI has three subscales: Goals, which reflects the agreement 514 between therapist and patient on overall goals of treatment; Tasks, which reflects the 515 agreement on the appropriate tasks on which to focus (to achieve goals); and Bond, the quality 516 of the affective relationship between the therapist and the patient. The WIA will be included to 517 examine therapeutic alliance as a potential moderator of treatment outcome, as well as to 518 examine potential treatment condition differences. The WAI therapist version will be completed 519 by the study therapists for each participant they treat, and the client version will be completed by 520 each participants enrolled in the RCT at the end of treatment. sessions compared with 12 sessions of treatment). If we conducted assessments at post-527 treatment for each treatment condition this would be problematic as assessing PTSD symptom 528 severity at different time points might confound outcome differences due to time rather than due 529 to treatment condition. To eliminate this possible confound, diagnostic assessments will be 530 conducted at the same time for all participants. See Table 1 for the Assessment Schedule. Both 531 treatment conditions will include approximately 3-, 6-and 12 month follow-up assessment. 532
There will be a total of 6 assessments for each participant enrolled in the study. Assessments 533 are conducted by independent evaluators (i.e., unaware of treatment condition) 534 535 Table 1 . Assessment Schedule 536
Baseline 6 weeks 12 weeks 24 weeks 36 weeks 60 weeks WET Post-tx 6 week f/u 3 month f/u 4.5 month f/u 13.5 month f/u CPT Mid-tx Post-tx 6 week f/u 3 month f/u 12 month f/u 537 Data Management. All study data will be entered into SPSS database, which will be housed on 538 a secure network server accessible only by project staff. The project coordinator will check all 539 data on the same day as entry to ensure completeness. Any incomplete data will be brought to 540 the attention of the independent assessor and/or therapist and every effort will be made to 541 complete ratings. All data will be entered twice by two different staff members, in order to detect 542 discrepancies. Field parameters will be specified such that suspect or missing values are either 543 disallowed or flagged for the immediate attention. Prior to data analysis, all data will be cleaned 544 and rechecked for accuracy before conducting data analysis. Three times per year, blinded data 545 will be compiled and reviewed by the PI and Co-I's to ascertain overall completeness and issues 546 requiring clarification, as well as for purposes of providing information to the data safety and 547 monitoring board. 548 549
Interventions 550
Treatment Conditions 551
Written Exposure Therapy (WET). The WET condition consists of 5 WET treatment sessions, 552
with the first session lasting 1 hour and each subsequent session lasting approximately 40 553 minutes. Sessions will be spaced one week apart and will take place in a private room located 554 within the National Center for PTSD (NC-PTSD). The first session will consist of the therapist 555 educating the participant about common reactions to trauma and providing information 556 regarding the rationale of WET as a treatment for PTSD. The participant will then be given 557 general instructions for completing the trauma narratives, specific instructions for completing the 558 first session, and will then complete the first (30 minutes) narrative writing session. Participants 559 will be instructed to write about the same trauma experience during each session. This event 560
will be the same event identified as the index trauma during the baseline assessment session.
561
The importance of delving into their deepest emotions surrounding the trauma event is 562 emphasized, as well as the importance of providing detailed information about the event. All 563 written exposure sessions will begin with the therapist given the specific instructions for written 564 exposure for that session and then leaving the instructions with the participant while 30 minute 565 writing session is completed. Written exposure instructions start with a focus on describing the 566 details of the trauma and emotions and thoughts that occurred during the trauma event and then 567 progress to a focus on the meaning of the trauma event (e.g., what the event has meant to the 568 person, how it has changed the way they view their life). 569 570
Cognitive Processing Therapy (CPT). CPT consists of 12, 60 minute sessions that primarily 571 focus on challenging and changing distorted beliefs and self-blame regarding the traumatic 572 event through Socratic questioning (Resick et al., 2002) . As previously described, an exposure 573 component is also included in the protocol; specifically, participants provide a written account of 574 their index event. See Appendix for CPT protocol. 575 576
Therapists: Background and assignment to condition: Therapists will hold either a masters 577 or doctoral degree. In the proposed study, we will counterbalance therapists across the two 578 treatment condition. 579 580 581
Therapists Training: Dr. Patricia Resick will train the CPT therapists during a two-day training 582 workshop. Dr. Sloan will train the WET therapists during a half-day training workshop. Both 583 training workshops will consist of reviewing the therapy protocol, discussing challenging issues 584 that can arise during each treatment protocol, and viewing videotaped sessions of therapists 585 delivering the treatment. The training workshops will be followed by a certification process 586 during which study therapists will conduct the respective treatments with pilot participants. Drs.
587
Resick and Sloan will review and rate the therapy sessions for competency and adherence. Dr. 588
Resick will be responsible for certifying therapists conducting CPT and Dr. Sloan will be 589 responsible for certifying therapists conducting WET. Competency ratings will be made on the 590 basis of skill of treatment delivery as well as adherence to the respective treatment protocol.
591
The competency ratings will range from a score of 1 (poor) to 7 (excellent). Study therapists in 592 both treatment conditions must minimally score at the acceptable level (score of 4) to be 593 deemed competent and ready to commence therapy with trial participants. In addition, therapist 594 competency and adherence will be monitored throughout the entire trial. Study therapists must 595 maintain the acceptable competency level in order to be able to continue as a study therapist. If 596 a study therapist falls below the minimal level of competency, then he/she will not be allowed to 597 provide any further treatment to participants until he/she is retrained and meets minimal 598 competency expectations.
599
In addition to competency certification and monitoring, study therapists will receive 600 weekly supervision from Dr. Resick for CPT and Dr. Sloan for WET. 601 602
Treatment fidelity and integrity will be assessed by two Treatment Adherence Raters who are 603 otherwise unaffiliated with the project. These two raters will be selected on the basis of their 604 familiarity with either WET or CPT. A randomly selected 20% of treatment sessions (equally 605 distributed between WET and CPT) will be reviewed and rated, using adherence and 606 competence forms 607 608
Sample size and Data Analysis Plan 609
We plan to conduct initial assessments on up to 220 participants in order to enroll 126 610 participants into the clinical trial. We have estimated the sample size needed to enroll 126 611 participants based on our collective experience conducting RCTs for PTSD 612 interventions. Typically, 70% of the individuals screened enroll in a PTSD clinical trial. Power 613 analyses indicated the need to enroll 126 participants, thus we will need to conduct initial 614 assessments on up to 220 participants in order to enroll 126 participants into this RCT. 615 616
Power analysis and sample size calculation: We calculated power and sample size 617 estimation using a 10 CAPS points noninferiority margin described above, and using an effect 618 size of .30 based on the assumption that a small effect size would be expected when comparing 619 two active treatments (Schnurr, 2007) . For a noninferiority trial such a large difference can be 620 allowed where the test treatment is favored over the standard treatment, but one needs to 621 account for a smaller difference (margin of .05 -.20) in the other direction -where the 622 comparator treatment is favored over the test treatment.
623
Using an effect size of .30 and corresponding margin effect size of at least .10, we estimate 624 needing a total of 100 participants. To account for a 20% attrition rate, we have increased our 625 sample size to 126. This power analysis is conservative given it does not take into 626 consideration the longitudinal observations analyzed with random effects models. Adjusting 627 for the longitudinal observations would increase power. 628 629
Data analysis plan 630
Primary Aim:Examine if WET therapy is noninferior to CPT 631 Hypothesis 1: Participants randomly assigned to WET therapy will show noninferior outcome in 632 PTSD symptom severity at the 12, 24, and 36 week post-first treatment session relative to 633 participants randomly assigned to CPT.
634
Hypothesis 2: Participants randomly assigned to WET therapy will show noninferior outcome in 635 PTSD symptom severity at the 60 week post-baseline assessment relative to participants 636 randomly assigned to CPT. 637 638
Following CONSORT guidelines for a noninferiority trial (Piaggio et al., 2006), we will conduct 639 an intent-to-treatment (ITT) analysis, which will be defined as all randomized participants who 640 attend at least the first therapy session. Random effects linear (hierarchical linear) models will 641 be implemented for the primary noninferiority ITT randomized comparison of total CAPS score 642 as well as any secondary analyses. This ITT comparison will disregard all CPT non-adherence 643 occurring after randomization under the ITT principal (Piaggio et al., 2006) . The random effects 644 linear models will consist of a random intercept and slope to account for within-patient 645 correlations for the longitudinal observations across follow-up visits (baseline to 6-, 12-, 24-, and 646 36-weeks post-baseline assessment). Fixed effects specified separately for each post-baseline 647 visit, the intervention, and their respective interactions will be used to obtain the ITT estimate 648 and one-sided 95% confidence interval for the noninferiority test of change from baseline at the 649 24 week post-baseline assessment. The test of noninferiority will be based on showing that this 650 upper bound of the one-sided confidence interval is less than the pre-specified margin of 10 651 CAPS points that is considered to show that WET is noninferior to CPT. The 12, 24, and 36 -652 week assessment visit will be used to test noninferiority (Hypo 1).. Noninferiority will be claimed 653 if the model-based difference between the two conditions is less than this upper bound. The 60 654 week post-baseline assessment will be used to examine Hypo 2, which concerns long term 655 maintenance of treatment gains. 656 657
This likelihood approach makes the most robust missing data assumption (missing at random) 658 among assumptions not involving untestable relationships between unobserved data and 659 missingness (Little 1995; Ten Have et al., 1998). As such, it includes CAPS data from all visits 660 at which the subject was measured, accommodating the variation in number of observed visits 661 per subject. We will employ residual analyses to assess normality and outliers of the CAPS and 662 other outcome variables. If the residual distributions are skewed, we will transform the outcome 663 to achieve more symmetric distributions.
664
The same random effects models will be implemented for assessing the effectiveness of CPT 665 relative to WET in terms of efficacy outcomes. However, the ITT tests will be tests of superiority 666 rather than inferiority. Accordingly, the above model-based estimates of CPT vs. WET 667 differences will be augmented with 95% confidence intervals and hypothesis tests of the 668 significance of the estimates. An alpha of .01 will be used to not only guard against type I 669 errors, but also avoid being too conservative and hence missing important exploratory findings 670 (Michels & Rosner 1996; Savits & Olshan 1995). 671 672
Secondary Aim: Examine whether there are treatment condition differences in treatment 673 dropout rate. Hypo 3: WET therapy will have a significantly lower dropout rate relative to CPT.
674
To examine the secondary aim we will conduct Chi square analyses with dropout frequency as 675 the dependent variable and treatment condition as the independent variable. Treatment dropout 676 will be defined as prematurely ending treatment prior to the completion of the treatment 677 protocol. 678 679
Exploratory analyses 680
We will conduct exploratory analyses to investigate treatment condition differences in outcome 681 for depression symptom severity using a noninferiority approach described above. We will also 682 examine whether there are treatment condition differences in terms of client satisfaction ratings 683 by performing an ANOVA, with treatment as the between subject factor and client satisfaction 684 total score as the dependent 
Resources
734
Each staff member working on the proposed study will have office space that will all be 735 located on the same wing of the medical center. Consequently, the PI and Co-I will be readily 736 accessible to research staff in the event of a patient crisis. All staff assigned to the proposed 737 project will have their own office space. All office spaces have phones with designated phone 738 numbers for each office. The PIs' office includes 2, four-drawer locked file cabinets, one of 739 which will be used to store screening forms, semi-structured interview data, data collected 740 during treatment sessions,and questionnaire data. As described previously, the Division has 741 mulitple rooms that are designated as therapy/assessment rooms. These rooms will be used for 742 conducting assessment and therapy sessions for the proposed study. All of the equipment (e.g., 743
digital recorders, computers) needed for the proposed study are already in place. 744 745
Human Subjects Section 746 RISKS TO THE SUBJECTS 747
a. Human subjects involvement and characteristics 748
The participant population is to be comprised of 126 men and women participants that will be 749 recruited on the basis of the presence of current PTSD diagnosis. These individuals will be 750 recruited on a volunteer basis. will precede all procedures. At the beginning of the first session participants will be fully 761 informed that they will be randomly assigned to one of two treatment conditions; a description of 762 each treatment will be provided to the participant. Participants will also be informed that they are 763 free to withdraw from the study at any time without any consequences. An in-depth debriefing 764 will explain all procedures and hypotheses, and answer any questions. The debriefing will be 765 conducted at the conclusion of the last follow-up assessment session. Participants will be told 766 that the exact nature of the study cannot be revealed to them until completion of the follow-up 767 visits to reduce any bias in the results. Any participant withdrawing early from the experiment 768 will be provided with a debriefing at time of withdrawal. 769 770
b. Sources of research materials 771
All information pertaining to this project (e.g., screening forms, questionnaire data, written 772 narratives, audio-recordings of assessment sessions and therapy sessions for both treatment 773 conditions) will be held in the strictest confidence and will be kept in locked files located within 774 the PI's office at VA Boston Healthcare System and will be available only to individuals directly 775 involved with the project. Under no circumstances will individually identifiable data be released 776 to anyone without written consent of the participant. Results will be published as group findings 777 only. Experimental results will be discussed with the participant at their request. Recording: Some participants may feel uncomfortable about the assessment and treatment 785 sessions being recorded. However, this will be a required procedure. The purpose of the 786 recording will be explained, confidentiality will be respected, and both informed consent and 787 authorization for recording will be obtained as per requirements put forth by the Healthcare 788 Information Portability and Accountability Act (HIPAA). Recordings will be marked only by 789 subject identification codes and stored in password protected computer server accessible only 790 to staff directly involved with the project. 791 792 Self-Report Measures and Assessor Ratings: No risks are seen associated with these 793 assessment procedures other than discomfort associated with the audio-recording. These will 794 be handled as described above for recording of assessment and therapy sessions. 795
796
ADEQUACY OF PROTECTION AGAINST RISKS 797 a. Recruitment and Consent Procedures 798
Following the recruitment procedures used in our recent PTSD clinical trial, we used a variety of 799 recruitment strategies (e.g., newspaper advertisements, sending brochures to healthcare 800 providers in the surrounding area); two strategies were most effective. These strategies were 801 posting flyer announcements in the community (e.g., near public transportation stops, in 802 community centers, public libraries, laundromats, grocery stores) and posting announcements 803 on Craigslist. We were able to recruit an average of 3 participants per month who met eligibility 804 criteria and enrolled in the clinical. We expect to be able to recruit a greater number of 805 participants for the proposed trial because we will be recruiting a broader sample of PTSD 806 participants.
807
The study announcements will state that the free treatment is part of a research study that is 808 available to qualified individuals. Interested individuals will be instructed to call for further 809 information.
811
In accordance with HIPAA regulations, written informed consent will be obtained from each 812 participant after a thorough explanation of procedures by a project staff person and the 813 opportunity for the participant to ask and receive answers to questions. Participants will be 814 informed of the nature of the investigation, the types of assessments and treatments involved, 815 alternative treatments, and the potential risks involved in participation and will be asked to sign 816 an informed consent statement prior to participating in the proposed study. In addition, the 817 participant will receive an explanation of how information related to their case will be handled 818 including all parties involved, data management, and plans to publish data in group format 819 without identifying information. 820
Participants will also be informed that confidentiality may be broken under the following 821 circumstances: disclosure of suicidal or homicidal intentions, disclosure of child abuse, 822 disclosure of elder abuse. Confidentiality may be broken in such instances in order for 823 protective measures to be taken.. 824 b. Protection against risk 825
1. We will carefully screen to identify individuals whose risk for potential adverse outcomes is 826 elevated were they to participate in the proposed research. Such individuals will be excluded 827 from the study. As an example, a person deemed high suicidal risk (assessed using the MINI 828 suicide module) would be excluded from study participation. These individuals will be 829 followed by study personnel (if they give consent to be followed). 830 831 2. Clinical staff will be trained to cope with any anxiety/distress experienced by participants 832 during the assessments and treatment. 833 834 3. Careful monitoring of participants during the initial assessment and throughout the study will 835 be conducted by the project staff. Participants will complete the PCL and BDI at each 836 assessment and treatment session in order to carefully monitor symptoms (and potential 837 symptom increases). Each participant will see the same clinician for each of their treatment 838 visits and the same assessor for each assessment occasion. Following the clinical trial policy 839 of the VA Boston Healthcare System, all participants will be given an emergency number to 840 call after business hours in case of an emergency. This number will be the psychiatry on call 841 system of the VA Boston Healthcare System. 842 843
4. Participants will be instructed to contact study personnel at any time (including during the 844 follow-up period) in the event of worsening of symptoms or relapse. Participants whose 845 clinical condition has substantially deteriorated will be removed from study treatment and 846
given appropriate clinical referrals will be made. These individuals will also be followed by 847 study personnel, if they give permission to be followed. See DSMP for details. 848 849 5. Participants failing to benefit from the study treatments will be provided with a list of clinical 850 referrals in the greater Boston area. Participants who begin treatment and experience 851 adverse outcomes sufficient to require removal from the study will receive appropriate clinical 852 referrals. The appropriate clinical referrals will be determined by the judgment of clinicians 853 and supervising staff familiar with the specific participant and may include cognitive-854 behavioral treatment, other psychotherapy, or referral for medication treatment.
856
6. As in any type of treatment or clinical research program, participants' confidentiality must be 857 carefully guarded and respected. All data with identifying information will be stored in locked 858 files or password-protected computer server. Data being analyzed will be identified by 859 subject codes, and identifying information will be removed. The identity of participants will not 860 be revealed in the presentation or publication of any results from the project. All personnel 861 working on the project will be educated about the importance of strictly respecting 862 participants' rights to confidentiality and will have completed several training courses 863 including proper practice in accordance with HIPAA regulations, protection of human 864 subjects, and computer security. 865 866
7. Establishment of a data safety monitoring committee (see DSMP section for details and for 867 additional information regarding protection against the risks). 868 869
POTENTIAL BENEFITS OF THE PROPOSED RESEARCH TO THE SUBJECTS AND
OTHERS 871
The direct benefit to participants who enter this study will be to obtain relief from anxiety 872 symptoms, decreased avoidance, decreased disability, and increased quality of life. For many 873 individuals with PTSD the disorder has greatly impeded their social, vocational, and academic 874 functioning. 875
IMPORTANCE OF THE KNOWLEDGE TO BE GAINED 877
Posttraumatic stress disorder (PTSD) is a chronic and debilitating disorder with a lifetime 878 prevalence rate of up to 25% (Kessler et al., 2005) . PTSD has been associated with substantial 879 costs, both in terms of health care utilization and work productivity. Despite the fact that several 880 empirically-supported psychotherapy treatments for PTSD exist, many of these individuals do 881 not present for treatment, in part, due to the cost and time commitment required for these 882 treatments. Establishing cost-effective, brief and readily deliverable alternatives to traditional 883 (time intensive) psychotherapy options for individuals with PTSD has broad public health and 884 policy implications given the high prevalence of this debilitating disorder. The proposed study 885 seeks to establish such an alternative treatment. 886
DATA SAFETY AND MONITORING PLAN (DSMP) 887
Data Safety and Monitoring Board (DSMB) 888
Given the scope of the current study, a formal DSMB is not required. We will form a Data 889
Monitoring Committee (DMC). The DMC will be comprised of 4 members who have expertise in 890 clinical trials, preferably expertise in PTSD, and who are not affiliated in any other way with the 891 proposed project. Each member of the DMC will work at VA Boston Healthcare System, which 892 will eliminate the need to include individuals who are outside of VA Boston. The DMC can 893 request unblinding of data if deemed necessary. Otherwise, group-level data will be provided to 894 the DMC. Following each quarterly meeting, the DMC will provide the PI with a written 895 summary of their review and recommendations. The PI will provide these quarterly summaries 896
to the VA Boston IRB as part of the annual review process. In addition, the PI will be 897 responsible for executing any recommended changes to the Data Safety and Monitoring Plan 898 and complying with the reporting requirements. 899
Protocol for Monitoring Adverse Events 900
We don't expect adverse events to occur as a result of study treatment. However, because of 901 the psychiatric nature of the sample to be studied, there is a potential for adverse events to 902 occur. These adverse events include suicidal ideation, homicidal ideation, and an increase in 903 PTSD symptom severity. Although the likelihood of these adverse events occurring in response 904 to PTSD treatment is low (e.g., Foa et al., 2002) , these adverse events will be closely monitored 905 throughout the study. Apart from these potential adverse events, we do not anticipate the 906 occurrence of any other adverse events. 907
As previously described, there are two reasons suicidal risk will be assessed in the proposed 908 study. The first reason is to determine participant eligibility and the second reason is to ensure 909 the safety and well-being of participants throughout the study. The Mini International 910
Neuropsychiatric Interview (MINI) suicide module will be used to assess suicide risk during the 911 baseline assessment. The MINI suicide module is a clinician administered interview that 912 consists of 9 questions related to suicidal ideation and behaviors, with possible scores ranging 913 from 0 to 53. Low suicide risk is defined as 0-8 points, moderate suicide risk is defined as 9-16 914 points, and high suicide risk is defined as scoring 17 or greater. To monitor suicide risk throughout the study, we will administer the BDI-II at each treatment and 926 assessment session. If a participant endorses suicidal ideation at any level in response to 927 question #9 (suicidal thoughts or wishes), a clinical assessor will administer the MINI suicidal 928 module. Participants deemed to be a high risk for suicide on the MINI (i.e., score of 17 or 929 higher) will be removed from the study treatment and appropriate actions will be taken. These 930 actions are described below in the data monitoring section. In addition, if the participant is 931 willing, they will continue to be followed by the PI. 932
Homicidal risk will be assessed using approach recommended by VA/DOD Clinical Practice 933
Guideline for Major Depressive Disorder (2009). At the initial assessment and at the beginning 934 of each treatment session, participants will be directly asked whether they have thoughts of 935 harming anyone. If the participant indicates they do have thoughts of harming someone, then 936 the clinician will ask whether the participant has an active plan or method to harm someone 937 (e.g., weapon in their home) and whom the participant wishes to harm. Further assessment will 938 take place for participants who indicate that they have an active plan or method. Specifically, 939 they will be asked whether they have ever lost control and acted violently and, if so, the severity 940 of reported past violent behavior will be assessed. If a participant indicates that they have 941 thoughts of harming someone and they have an active plan, the participant will be considered 942 potentially high risk and further assessment will be conducted, as described in the section on 943 managing adverse events. 944
We will monitor for a substantial increase in PTSD symptom severity using the Posttraumatic 945
Check List (PCL; Weathers et al., 1994) . The PCL is a 17 item self-report measure of PTSD 946 symptom severity. This measure will be completed at each assessment session and each 947 treatment session. A substantial increase in symptoms is defined as at least 10 point increase 948
in PTSD from the initial assessment and has been sustained for a three week period (Foa et al., 949 2002) . 950
Protocol for Managing Adverse Events 951
In the event a participant is deemed high suicide and/or homicidal risk, staff will immediately 952 locate either the PI or one of the Co-I's (Drs. Marx and Resick), all of whom are licensed 953 psychologists. At least one of these individuals will be on-site when assessment and treatment 954 sessions are conducted. The PI or Co-I will intervene by a) following up with direct questions 955 about suicidal/homicidal behaviors, b) assess mental status by asking about psychotic 956 symptoms, mood symptoms and drug and alcohol use, c) schedule extra contacts if necessary, 957 emphasizing problem solving, d) help the participant generate short-term objectives, and e) 958 negotiate an action plan. The action plan will be collaboratively generated by the investigator 959 and the participant. The plan will address what actions need to be taken in the succeeding days 960
to solve the problems that precipitated suicidal/homicidal behavior. The plan will also address 961 the use of voluntary and involuntary hospitalization, if necessary. Lastly, in the case of homicidal 962 ideation with explicit intent to harm a named individual, the PI will report the intent to the local 963 police as required legally required to protect the named individual. 964
In addition to these formal assessments, all participants will be given the number of the on-call 965 psychiatry service at VA Boston Healthcare System and informed that they should call this 966 number after business hours in the event that they are feeling suicidal and/or distressed, or 967 homicidal. During business hours the participants will be instructed to contact the PI. Should a 968 participant call to indicate suicidal/homicidal risk, then the previously described intervention plan 969 will be followed. Participants will also be informed during the informed consent process that if 970 suicidal and/or homicidal intentions are disclosed confidentiality may be broken in order for 971 protective measures to be taken. In the event that a participant experiences an increase in PTSD symptom severity but without 976 suicidal/homicidal risk, the PI will intervene by asking direct questions about the nature and 977 causes of the distress, conduct a PTSD assessment, and schedule extra contacts 978 (assessments) if deemed necessary. Such individuals will be terminated from the protocol if 979 they report a substantial increase in the PTSD symptom severity (i.e. at least 10 points higher 980 than their baseline PTSD symptom severity score) that is sustained over a three week period.
981
We have selected the 10 point increase and 3-week time frame based on Foa, Zoellner et al.
982
(2002) in which they emphasize the importance of using a reliable index score when considering 983 increases (and decreases) in PTSD symptoms. Importantly, Foa and colleagues (2002) have 984 reported that only a minority of participants showed an acute substantial increase in PTSD 985 symptom severity during Prolonged Exposure treatment, and that this acute increase was not 986 associated with an increased risk for dropout or poor treatment outcome. Nevertheless, to 987 protect against risk, we will monitor participants for undue distress reactions and will use a 10 988 point increase from baseline assessment of PTSD symptom severity that is sustained for 3 989 weeks as a guide for withdrawing a participant from the study treatment. If a participant is 990 withdrawn from the study treatment, they will be followed by study personnel, if they agree to be 991 followed. In addition, participants who are withdrawn from the study treatment or who are 992 deemed ineligible to enroll in the trial will be provided with a list of clinical referrals that are 993 located in the greater Boston area. The referral list will include clinics that have a sliding scale 994 fee schedule. Study personnel will discuss with the participant which referrals are the most 995 viable given their personal circumstances (e.g., healthcare insurance restrictions, financial 996 restrictions, etc.). The PI will subsequently contact these participants within one week to make 997 sure that the participant did not experience any barriers in following through with clinical 998 referrals. 999
Protocol for Reporting Adverse Events 1000
